Phuturdex › Diseases › Cutaneous Squamous Cell Carcinoma
Drugs in development · updated 11 November 2026
Cutaneous Squamous Cell Carcinoma: drugs in development
What it is
Cutaneous squamous-cell carcinoma (cSCC), also known as squamous-cell carcinoma of the skin or squamous-cell skin cancer, is one of the three principal types of skin cancer, alongside basal-cell carcinoma and melanoma. cSCC typically presents as a hard lump with a scaly surface, though it may also present as an ulcer. Onset and development often occurs over several months. Compared to basal cell carcinoma, cSCC is more likely to spread to distant areas. When confined to the epidermis, the outermost layer of the skin, the pre-invasive or in situ form of cSCC is termed Bowen's disease.
Description not checked by Phuturdex: excerpt from the introduction of the article “Cutaneous squamous-cell carcinoma” on English Wikipedia, en.wikipedia.org · version of 13 October 2026 · licence CC BY-SA 4.0.
As of 11 November 2026 there are 8 active clinical trials (recruiting or ongoing, phases I–III) on 10 drugs for cutaneous Squamous Cell Carcinoma. 5 are experimental, that is not yet approved in the United States.
In Phuturdex every drug has its map of sites in Europe, every trial and its alerts, and you get an email when something changes. Full access free until 31 March 2027, no card needed.
Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Becotatug VedotinMRG003 | II | 1 | NCT07394244 |
| Ipilumimab | II | 1 | NCT06823479 |
| IvonescimabAK112 | II | 1 | NCT06567314 |
| PucotenlimabHX008 | II | 1 | NCT07394244 |
| SirolimusRapamycin, Hyftor® | II | 1 | NCT07715734 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CemiplimabREGN2810, Libtayo® | III | 3 | NCT03969004 |
| NivolumabONO-4538, Opdivo | II | 3 | NCT06288191 |
| RelatlimabRelatilmab | II | 2 | NCT06288191 |
| CetuximabErbitux, C225 | II | 1 | NCT07715734 |
| PrednisonePredinisone | II | 1 | NCT07715734 |
Sorted by most advanced phase and number of active trials.
Sites in Europe
87 sites of the active trials in 11 European countries, 7 recruiting.
- Italy18
- Spain14
- France13
- Germany12
- United Kingdom7
- Austria6
- Netherlands5
- Poland5
- and 3 more
Sites declared by the sponsors on ClinicalTrials.gov; region worked out by Phuturdex from the geographic point. The list of sites with city and recruitment status is in the app. See the sites →
All 10 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
- Neoplasm 3,413 drugs
- Skin disease 1,339 drugs
- Skin and connective tissue diseases 1,499 drugs
- Carcinoma 964 drugs
- Glandular and epithelial neoplasm 1,209 drugs
- Skin neoplasm 367 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 11 November 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D000099314 “Cutaneous Squamous Cell Carcinoma”.
8 of these trials have no NLM disease code: the code is assigned by Phuturdex, because the condition written by the trial is exactly a name in the NLM MeSH disease vocabulary (Method).